Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease

Scott, Ian; Houslay, Kirsty F.; Cohen, E. Suzanne

doi:10.21037/atm.2016.11.74

Cited by 12 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies that inhibit IL-33 signaling are in clinical development 186 TSLP/TSLPR Anti-TSLP, Tezepelumab Administration reduced lung inflammation and airways bronchoconstriction in mild asthma, and lowered rates of asthma exacerbations in patients with uncontrolled asthma 155,187 IL-9/IL-9R Anti-IL-9 and anti-IL-9R, MEDI-528 Humanized IL-9 antagonist that inhibits features of asthma in preclinical experimental models. No available data in humans 188 Prostaglandin pathway CRTH2 antagonists, OC000459 (Timapiprant), BI 671800, AZD1981, Fevipiprant…”

Section: Introductionmentioning

confidence: 99%

Pulmonary group 2 innate lymphoid cells: surprises and challenges

et al. 2019

View full text Add to dashboard Cite

Group 2 innate lymphoid cells (ILC2s) are a recently described subset of innate lymphocytes with important immune and homeostatic functions at multiple tissue sites, especially the lung. These cells expand locally after birth and during postnatal lung maturation and are present in the lung and other peripheral organs. They are modified by a variety of processes and mediate inflammatory responses to respiratory pathogens, inhaled allergens and noxious particles. Here, we review the emerging roles of ILC2s in pulmonary homeostasis and discuss recent and surprising advances in our understanding of how hormones, age, neurotransmitters, environmental challenges, and infection influence ILC2s. We also review how these responses may underpin the development, progression and severity of pulmonary inflammation and chronic lung diseases and highlight some of the remaining challenges for ILC2 biology.Mucosal Immunology (2019) 12:299-311; https://doi.

show abstract

Section: Introductionmentioning

confidence: 99%

Pulmonary group 2 innate lymphoid cells: surprises and challenges

et al. 2019

View full text Add to dashboard Cite

show abstract

“…These studies strongly suggest that expanded ILC2s may be a potent cellular therapy for the treatment of the lower GI tract GVHD [ 58 ]. Recently, it has been reported that third-party ILC2s prevent and treat gastrointestinal (GI) tract GvHD [ 3 , 59 ]. Previously, it has been reported that an elevated level of soluble ST2 (IL33 receptor) in patients was associated with insufficiency of therapeutic response for GVHD on day 28 and increased mortality after 6 months following the allogeneic stem cell transplantation [ 60 , 61 ].…”

Section: Ilc2 and Stem Cellsmentioning

confidence: 99%

Stem Cell Therapy and Innate Lymphoid Cells

Verma

Mishra³

2022

Stem Cells International

View full text Add to dashboard Cite

Innate lymphoid cells have the capability to communicate with other immune cell types to coordinate the immune system functioning during homeostasis and inflammation. However, these cells behave differently at the functional level, unlike T cells, these cells do not need antigen receptors for activation because they are activated by the interaction of their receptor ligation. In hematopoietic stem cell transplantation (HSCT), T cells and NK cells have been extensively studied but very few studies are available on ILCs. In this review, an attempt has been made to provide current information related to NK and ILCs cell-based stem cell therapies and role of the stem cells in the regulation of ILCs as well. Also, the latest information on the differentiation of NK cells and ILCs from CD34+ hematopoietic stem cells is covered in the article.

show abstract

“…To exploit the translational potential of IL-33/ST2-based therapies, a better understanding of differences in pharmacology between sST2 and anti-ST2 is needed. 184 Also, caution must be exercised in assessing the translational relevance of studies with injection of recombinant IL33, which might not reflect endogenous levels. Several strategies that aim at blocking IL33 signaling are nowadays feasible in patients.…”

Section: Unresolved Issues and Future Directionsmentioning

confidence: 99%

Conflicting vascular and metabolic impact of the IL-33/sST2 axis

Altara

Ghali

Mallat

et al. 2018

Cardiovascular Research

112

107

View full text Add to dashboard Cite

Interleukin 33 (IL-33), which is expressed by several immune cell types, endothelial and epithelial cells, and fibroblasts, is a cytokine of the IL-1 family that acts both intra- and extracellularly to either enhance or resolve the inflammatory response. Intracellular IL-33 acts in the nucleus as a regulator of transcription. Once released from cells by mechanical stress, inflammatory cytokines, or necrosis, extracellular IL-33 is proteolytically processed to act in an autocrine/paracrine manner as an 'alarmin' on neighbouring or various immune cells expressing the ST2 receptor. Thus, IL-33 may serve an important role in tissue preservation and repair in response to injury; however, the actions of IL-33 are dampened by a soluble form of ST2 (sST2) that acts as a decoy receptor and is produced by endothelial and certain immune cells. Accumulating evidence supports the conclusion that sST2 is a biomarker of vascular health with diagnostic and/or prognostic value in various cardiovascular diseases, including coronary artery disease, myocardial infarction, atherosclerosis, giant-cell arteritis, acute aortic dissection, and ischaemic stroke, as well as obesity and diabetes. Although sST2 levels are positively associated with cardiovascular disease severity, the assumption that IL-33 is always beneficial is naïve. It is increasingly appreciated that the pathophysiological importance of IL-33 is highly dependent on cellular and temporal expression. Although IL-33 is atheroprotective and may prevent obesity and type 2 diabetes by regulating lipid metabolism, IL-33 appears to drive endothelial inflammation. Here, we review the current knowledge of the IL-33/ST2/sST2 signalling network and discuss its pathophysiological and translational implications in cardiovascular diseases.

show abstract

Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease

Cited by 12 publications

References 25 publications

Pulmonary group 2 innate lymphoid cells: surprises and challenges

Pulmonary group 2 innate lymphoid cells: surprises and challenges

Stem Cell Therapy and Innate Lymphoid Cells

Conflicting vascular and metabolic impact of the IL-33/sST2 axis

Contact Info

Product

Resources

About